Efficacy and acceptability of tianeptine in major depressive disorder and in dysthymia (DSM-IIIR) with somatic complaints: double blind study versus fluoxetine

Alby, J. M.; Cabané, J.; Ferreri, M.; Bougerol, Thierry

doi:10.1016/0924-977x(93)90110-8

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of efficacy, this study showed that both drugs significantly decrease depression scores and CGI scores from baseline to end point, with a twothirds, percentage of responders, and failed to show differences between drugs except for the CGI severity The results of this study are consistent with those of previous studies comparing tianeptine to selective serotonin reuptake inhibitors, such as fluoxetine (Alby et al, 1993;Lôo et al, 1999), paroxetine (Lepine et al, 2001) or sertraline (Szádóczky and Füredi, 2000). In terms of safety, the results of this study are also consistent with those of previous studies comparing tianeptine with selective serotonin reuptake inhibitors.…”

Section: Discussionsupporting

confidence: 91%

Tianeptine and fluoxetine in major depression: a 6‐week randomised double‐blind study

Faltus

2002

Human Psychopharmacology

View full text Add to dashboard Cite

In a 6-week, multicentre, randomised, double-blind controlled study, tianeptine (37.5 mg/day) and fluoxetine (20 mg/day) were compared for efficacy and safety in 178 patients with major depression. No significant difference was shown between the two drugs, either in terms of efficacy (MADRS, CGI, COVI) or in terms of safety, except for the CGI 'severity of illness' which was lower at the end point with tianeptine than with fluoxetine. The percentages of responders (as defined by a 50% decrease of the MADRS score from baseline to end point) were 75% with tianeptine and 67% with fluoxetine, showing the efficacy of both drugs. In conclusion, both tianeptine and fluoxetine are effective and well-tolerated treatments for major depression.

show abstract

Section: Discussionsupporting

confidence: 91%

Tianeptine and fluoxetine in major depression: a 6‐week randomised double‐blind study

Faltus

2002

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Tianeptine is an atypical tricyclic compound, for which antidepressant ef®cacy has been well established, particularly in comparison with amitriptyline (Lôo et al, 1988;Guel® et al, 1989), imipramine (Cassano et al, 1996),¯uoxetine (Alby et al, 1993;Lôo et al, 1999) and placebo (Cassano et al, 1996;Costa e Silva et al, 1997;Dalery et al, 2001). Preclinical and clinical studies suggest that it may have some anxiolytic properties in depressed patients.…”

Section: Introductionmentioning

confidence: 97%

Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6‐week double‐blind study†

Lépine

Altamura

Ansseau

et al. 2001

Human Psychopharmacology

View full text Add to dashboard Cite

Tianeptine (37.5 mg/day) and paroxetine (20 mg/day) were compared in a population of depressive patients without past or current history of co-morbid anxiety and/or important anxiolytic treatment. In a 6-week, double blind trial, the special focus was on anxious symptoms.Both drugs showed good efficacy on depressive symptomatology, assessed with MADRS and HDRS, but no difference was detected between tianeptine and paroxetine, for any assessment criterion. Despite the choice of selected depressive patients, without any co-morbid anxious disorder, anxiety scale scores at inclusion (HAMA and BAS) were appreciable but correlated poorly with depressive scores. Both tianeptine and paroxetine improved the apparent anxious component in depression. Tolerability of both drugs was good, although significantly better with tianeptine.Thus tianeptine and paroxetine are effective and safe treatments for major depression and may also act directly on the anxious component of the psychopathology. Copyright 2001 John Wiley & Sons, Ltd.

show abstract

Pharmacotherapy for dysthymia

Lima

Hotopf²

2003

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Efficacy and acceptability of tianeptine in major depressive disorder and in dysthymia (DSM-IIIR) with somatic complaints: double blind study versus fluoxetine

Cited by 8 publications

References 0 publications

Tianeptine and fluoxetine in major depression: a 6‐week randomised double‐blind study

Tianeptine and fluoxetine in major depression: a 6‐week randomised double‐blind study

Tianeptine and paroxetine in major depressive disorder, with a special focus on the anxious component in depression: an international, 6‐week double‐blind study†

Pharmacotherapy for dysthymia

Contact Info

Product

Resources

About